Fiscal year 2014: Renewed sales growth and sharply higher profits

March 20, 2015
Bachem building at the Bubendorf manufacturing site

Bubendorf/Basel, March 20, 2015 – Bachem Group (SIX: BANB), the technology leader in the field of peptide chemistry with a focus on quality and innovation, performed well in fiscal year 2014. The Group generated sales of 183.9 million CHF (2013: 170.7 million CHF, +7.8% in CHF and +7.9% in local currency/LC). Thanks to targeted cost-savings and further efficiency gains, operating profit (EBIT) increased by 21.8% to 35.9 million CHF. This figure includes a gain of 2.0 million CHF on the divestment of the non-core immunology product line. The EBITDA margin amounted to 29.9%, the EBIT margin was 19.5%. Net income rose by 23.1% to 29.1 million CHF. Bachem thus met its communicated sales targets in full amid an ongoing competitive market environment and grew its net income at a proportionally much faster rate after already reporting a 51.7% increase in net income for the previous fiscal year.


At Bachem, we believe that our employees make the difference. Representing our corporate culture of passion and commitment, they are the foundation of our success. We therefore strive to attract, retain, and develop highly motivated, well-qualified individuals.

View all jobs

Click here >>

Contact us


  • Please choose if you would like to receive additional email communications from Bachem:

  • Fields marked with an asterisk (*) are required

  • Hidden
  • Hidden
  • This field is for validation purposes and should be left unchanged.